Brenda Bradfield, BSN, CDE, works on the frontlines of type 1 diabetes (T1D) research at the Barbara Davis Center for Diabetes at the University of Colorado Anschutz Medical Campus.

Elliot, a 17-year-old from a small village outside Bristol, recently completed treatment in the Abatacept Prevention Study. He is the first person in the United Kingdom (UK) to do so.

In a two-year study wrapping up at year's end, frozen blood samples from previous TrialNet study participants who did not receive the study drug played a starring role.